Wockhardt Limited - Asset Resilience Ratio
Wockhardt Limited (WOCKPHARMA) has an Asset Resilience Ratio of 5.19% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Wockhardt Limited to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Wockhardt Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see WOCKPHARMA total asset value.
Liquid Assets Composition Over Time
This chart breaks down Wockhardt Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Wockhardt Limited strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs4.22 Billion | 5.19% |
| Total Liquid Assets | Rs4.22 Billion | 5.19% |
Asset Resilience Insights
- Limited Liquidity: Wockhardt Limited maintains only 5.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Wockhardt Limited Industry Peers by Asset Resilience Ratio
Compare Wockhardt Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Wockhardt Limited (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Wockhardt Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 5.19% | Rs4.22 Billion ≈ $45.64 Million |
Rs81.35 Billion ≈ $879.77 Million |
+4.98pp |
| 2024-03-31 | 0.21% | Rs160.00 Million ≈ $1.73 Million |
Rs76.49 Billion ≈ $827.21 Million |
-1.01pp |
| 2023-03-31 | 1.22% | Rs940.00 Million ≈ $10.17 Million |
Rs76.83 Billion ≈ $830.89 Million |
+1.11pp |
| 2022-03-31 | 0.11% | Rs90.00 Million ≈ $973.32K |
Rs82.43 Billion ≈ $891.45 Million |
+0.04pp |
| 2021-03-31 | 0.07% | Rs54.40 Million ≈ $588.32K |
Rs77.73 Billion ≈ $840.59 Million |
-0.49pp |
| 2020-03-31 | 0.56% | Rs457.30 Million ≈ $4.95 Million |
Rs81.79 Billion ≈ $884.52 Million |
-0.92pp |
| 2019-03-31 | 1.48% | Rs1.16 Billion ≈ $12.54 Million |
Rs78.31 Billion ≈ $846.90 Million |
-3.42pp |
| 2018-03-31 | 4.90% | Rs4.00 Billion ≈ $43.26 Million |
Rs81.62 Billion ≈ $882.69 Million |
-13.38pp |
| 2017-03-31 | 18.28% | Rs16.39 Billion ≈ $177.29 Million |
Rs89.69 Billion ≈ $969.93 Million |
+8.10pp |
| 2016-03-31 | 10.18% | Rs8.10 Billion ≈ $87.56 Million |
Rs79.52 Billion ≈ $860.00 Million |
+4.34pp |
| 2015-03-31 | 5.85% | Rs4.06 Billion ≈ $43.87 Million |
Rs69.39 Billion ≈ $750.41 Million |
-3.13pp |
| 2014-03-31 | 8.97% | Rs5.94 Billion ≈ $64.26 Million |
Rs66.22 Billion ≈ $716.15 Million |
+8.97pp |
| 2013-03-31 | 0.00% | Rs2.70 Million ≈ $29.20K |
Rs60.40 Billion ≈ $653.21 Million |
-4.60pp |
| 2011-03-31 | 4.61% | Rs2.71 Billion ≈ $29.34 Million |
Rs58.89 Billion ≈ $636.83 Million |
-3.87pp |
| 2010-03-31 | 8.48% | Rs4.85 Billion ≈ $52.50 Million |
Rs57.26 Billion ≈ $619.21 Million |
-0.89pp |
| 2009-03-31 | 9.37% | Rs6.31 Billion ≈ $68.20 Million |
Rs67.28 Billion ≈ $727.62 Million |
+5.71pp |
| 2008-03-31 | 3.66% | Rs1.89 Billion ≈ $20.42 Million |
Rs51.53 Billion ≈ $557.29 Million |
-33.74pp |
| 2005-03-31 | 37.41% | Rs7.18 Billion ≈ $77.63 Million |
Rs19.19 Billion ≈ $207.51 Million |
-- |
About Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH… Read more